Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.

Annals of the American Thoracic Society - 1 Sept 2015

Torphy Theodore J, Allen Janet, Cantin André M, Konstan Michael W, Accurso Frank J, Joseloff Elizabeth, Ratjen Felix A, Chmiel James F

Abstract excerpt

Inflammation leads to lung destruction and loss of pulmonary function in patients with cystic fibrosis (CF). Drugs that modulate the cystic fibrosis transmembrane conductance regulator (CFTR) have recently been approved. Although the impact of CFTR modulators on sweat chloride and lung function are exciting, they have not yet demonstrated an effect on inflammation. Therefore, CF antiinflammatory drug development...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Anti-Inflammatory Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Neutrophils

Source

Identifiers

PMID: 26146892
DOI: 10.1513/AnnalsATS.201506-361OT

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.PMID 26146892Read ↗

Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction.Semantic proximity Read ↗

Unmet needs in cystic fibrosis.Semantic proximity Read ↗

Update on new pulmonary therapies.Semantic proximity Read ↗

The Effects of Nano-Curcumin as A Nutritional Strategy on Clinical and Inflammatory Factors in Children with Cystic Fibrosis: A Protocol Study and Review ArticleSemantic proximity Read ↗

The Role of Triple CFTR Modulator Therapy in Reducing Systemic Inflammation in Cystic FibrosisSemantic proximity Read ↗

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.Semantic proximity Read ↗

A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity Read ↗

The effect of highly effective modulator therapy on systemic inflammation in cystic fibrosisSemantic proximity Read ↗

The Role of MMPs in the Era of CFTR Modulators: An Additional Target for Cystic Fibrosis Patients?Semantic proximity Read ↗

Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid.Semantic proximity Read ↗

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.Semantic proximity Read ↗

Trials and tribulations of highly effective modulator therapies in cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.